Category: Health Science
-
Medexus Pharmaceuticals (MDP.V), Flexing its deal making muscles
Buckle up everyone, and get excited – let’s break down Medexus’ latest press release with all its technical details. This is a two-parter, because Medexus not only has closed an important deal that has relevancy for blood cancer treatments, but it’s also upsized its current financing – a financial move that’s indicative of the growing…
-
![PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)]()
PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)
Ok weekenders, let’s talk PMED. For the newbies in the room, PMED is PredictMedix Inc, a biotech company Equity Guru’s been working with for the past little bit. (Of course, this doesn’t change the fact that we’re still big on holding people accountable – client or not. See recent example here.) PMED as a business…
-
Medexus Pharmaceuticals (MDP.V), poised for flight on the Nasdaq (coming soon)
If you are like me and health sciences is your sector of choice when it comes to investing in the markets, you’d better be very patient, love doing research – and a willingness to see it through!!! A sector famous for its high-risk-high-reward characteristics is definitely not recommended for the faint of heart. Lucky for…
-
![Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale]()
Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In…
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
-
Immunoprecise Antibodies (IPA.V), or should I say (NASDAQ: IPA)
Before we start, let’s give a big round of applause to Immunoprecise Antibodies Ltd and all its staff and its management. They are headed to the big leagues, ladies and gentlemen – a straight path towards listing on the Nasdaq (begin trading on Nasdaq on December 30th, 2020). I’m not a parent myself (unless you…
-
Perimeter Medical Imaging AI (PINK.V): the power of a simple story
No need to cut the patient open again later. The surgeon can make adjustments on the fly.
-
Revive Therapeutics (RVV.C) shareholders experience intense vertigo
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
-
Can scrappy Valeo Pharma (VPH.C) win a Stanley Cup?
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
